The question that Novartis will ultimately answer is whether if MTD has been established, have they seen enough hearing improvement to go to the Phase 2 portion of the trial. If not, the question becomes, do they go to a multi dose trial using lower doses. They might choose to wait for the other drug GNVC is developing to supplement this drug, or they could abandon it completely.
As I indicated earlier, this could take quite some time. I believe GNVC share price is an over reaction to the news, and it's a strong buy at these prices.
Gary
Market Data 
Markets 
AI
